way-202196 has been researched along with Bacteremia* in 1 studies
1 other study(ies) available for way-202196 and Bacteremia
Article | Year |
---|---|
WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock.
To determine the effect of an estrogen receptor-beta selective agent in experimental models of systemic infection and sepsis.. WAY-202196, a nonsteroidal selective estrogen receptor-beta agonist, was tested in the murine listeriosis model, the neutropenic rat Pseudomonas aeruginosa infection, and the mouse cecal ligation and puncture sepsis models.. University-affiliated biomedical research laboratory.. BALB/c mice and Sprague-Dawley rats.. WAY-202196 or control (vehicle) was administered orally in doses ranging from 1.5 to 50 mg/kg at various time points in the three experimental model systems.. Susceptibility of mice treated with a single oral dose of up to 50 mg/kg WAY-202196 did not differ from those treated with vehicle alone after systemic challenge by Listeria monocytogenes, suggesting a lack of generalized immunosuppression. In the neutropenic rat model, daily administration of WAY-202196 (50 mg/kg) significantly increased survival against an otherwise lethal challenge of P. aeruginosa 12.4.4 compared with the control group (83% vs. 25% survival; p < 0.05). Preservation of intestinal mucosal weight and prevention of histopathologic changes were also observed with the administration of WAY-202196. Similar results were obtained in a cecal ligation and puncture model, in which multiple oral doses of WAY-202196 (50 mg/kg) improved survival (83% vs. 0%; p < 0.05), preserved intestinal epithelial integrity, and significantly reduced systemic bacteremia and peritoneal interleukin-6 and tumor necrosis factor levels. The estrogen receptor-beta agonist provided a comparable level of protection in both male and female animals.. These results indicate that oral administration of WAY-202196 preserved gastrointestinal barrier function and improved outcome in experimental models of systemic infection and inflammation. WAY-202196 and similar agents may prove useful clinically as a novel treatment strategy for the treatment or prevention of severe sepsis. Topics: Administration, Oral; Animals; Ascitic Fluid; Bacteremia; Disease Models, Animal; Estrogen Receptor beta; Female; Interleukin-6; Intestinal Mucosa; Listeria monocytogenes; Male; Mice; Mice, Inbred BALB C; Naphthols; Neutropenia; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Shock, Septic; Tumor Necrosis Factor-alpha | 2006 |